Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H25N4O11P2.Na |
Molecular Weight | 510.3058 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].C[N+](C)(C)CCOP([O-])(=O)OP([O-])(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(N)=NC2=O
InChI
InChIKey=YWAFNFGRBBBSPD-OCMLZEEQSA-M
InChI=1S/C14H26N4O11P2.Na/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21;/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25);/q;+1/p-1/t9-,11-,12-,13-;/m1./s1
Molecular Formula | C14H25N4O11P2 |
Molecular Weight | 487.316 |
Charge | -1 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Citicoline (CDP-choline; cytidine 5'-diphosphocholine) is a novel nutrient with a broad spectrum of benefits for conditions associated with symptoms of neurological dysfunction shows promise of clinical efficacy in elderly patients with cognitive deficits, inefficient memory, and early-stage Alzheimer's disease. Citicoline has also been investigated as a therapy in stroke patient. Despite it was approved in some countries for treatment Traumatic Brain Injury (TBI), the use of this drug for acute TBI seems to have no field of support anymore, whereas it may have some benefits in improving the neuro-cognitive state in chronic TBI patients. It's also recommended to keep in mind acute interventions like Psychological First Aid (PFA) during acute TBI management. Citicoline plays several important roles in human physiology, including enhancement of structural integrity and signaling for cell membranes, support of acetylcholine synthesis, and synthesis of betaine, a methyl donor. The precise mechanism of action of Citicoline to treat disease is unknown, but was confirmed, that drug might increase phosphatidylcholine (PtdCho) synthesis and might reverse PtdCho loss. In addition, was shown, that citicoline modulates phospholipids metabolism and neurotransmitter levels and appears to improve cognition in some central nervous system disorders such as bipolar disorder and cocaine dependence. Bipolar disorder is associated with the highest rates of substance abuse of any psychiatric disorder. Cocaine use is particularly common in patients with bipolar disorder.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: phosphatidylcholine Sources: https://www.ncbi.nlm.nih.gov/pubmed/12021827 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of citicholine and of the combination citicholine + piracetam on the memory (experiments on mice). | 1990 |
|
Citicoline improves memory performance in elderly subjects. | 1997 Apr |
|
A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. | 1997 Sep |
|
Cytidine-5'-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. | 1998 Feb |
|
Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke. | 2013 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00545662
1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23227823
Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells (EC) through pathways involving ERK1/2 and insulin receptor substrate-1. hCMEC/D3 cells were seeded at a concentration of 8 × 104 cells/ml in 500 μl of complete basal medium in each well of 24-well plate. After 4 h, the medium was changed to serum-poor medium (SPM) containing 1% FBS containing different concentrations of citicoline (1 μM, 10 μM and 100 μM; NOTE; pilot experiments were carried out using 1-100 μM citicoline and optimized for the use of 10 μM subsequently as this produced the most prominent responses). It was discovered that insulin receptor substrate-1 (IRS-1) represented a potent modulator of pro-angiogenic signalling cascades in vascular EC, thus was shown that citicoline induces phosphorylation of IRS-1 and concomitant EC activation and increased vascularisation, that could be a key novel mechanism of action of citicoline.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:22:17 GMT 2023
by
admin
on
Fri Dec 15 15:22:17 GMT 2023
|
Record UNII |
7XQ5AKD9YD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1134305
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
DTXSID4048981
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
100000092641
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL1618340
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
33818-15-4
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
C171765
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
1099914
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT002146
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
7XQ5AKD9YD
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
251-689-1
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
m3588
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB01321MIG
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
36605
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
GG-60
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |